Coherus Oncology Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $50.9M+93.0% YoYTTM through 30 Jun 2026
Net Income -$132.1M-563.5% YoYTTM through 30 Jun 2026
Free Cash Flow -$186MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 67.2% |
| EBITDA Margin | -309.0% |
| Operating Margin | -429.5% |
| Net Margin | -259.4% |
Returns
-300.1%ROE
-70.9%ROA
Balance Sheet Health
Debt / Equity0.61x
Current Ratio1.77x
Net Debt-$135.1Mnet cash position
Cash & Equivalents$82.9M
Quality Metrics
Altman Z-Score-11.74
Piotroski F-Score2 / 9
FCF Margin-365.2%
Rule of 40-321.9
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $42.2M
Diluted EPS-$1.05TTMFY2025: $1.43
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| LOQTORZI (toripalimab-tpzi) | $40.8M | +113.6% | View detailsTargeting expansion in nasopharyngeal carcinoma (NPC) and evaluating proprietary combinations with pipeline candidates casdozokitug and tagmokitug. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.